netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 4: Central nervous system - Full Chapter
04.04  Expand sub section  CNS stimulants and other drugs used for attention deficit hyperactivity disorder
Atomoxetine (Strattera)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber E

Atomoxetine (as Atomoxetine hydrochloride) Capsule 10mg 
Atomoxetine (as Atomoxetine hydrochloride) Capsule 18mg 
Atomoxetine (as Atomoxetine hydrochloride) Capsule 25mg 
Atomoxetine (as Atomoxetine hydrochloride) Capsule 40mg 
Atomoxetine (as Atomoxetine hydrochloride) Capsule 60mg 
Atomoxetine (as Atomoxetine hydrochloride) Capsule 80mg 
Atomoxetine (as Atomoxetine hydrochloride) Capsule 100mg

Restriction: Initiation and stabilisation by specialist

Medicines for Children Leaflet: Atomoxetine for ADHD

Link to ESCA

 
   
Controlled Drug Dexamfetamine Sulfate

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber E

Dexamfetamine Sulfate Tablet 5mg

Restriction: Initiation and stabilisation by specialist

Link to ESCA

 
   
Controlled Drug Methylphenidate hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber E

Restriction: Initiation and stabilisation by specialist

Note Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of methylphenidate, prescribers should specify the brand to be dispensed.

Medicines for children leaflet: Methylphenidate for ADHD

Link to ESCA

 
Link  UKMI Q&A: Methylphenidate use for adults with ADHD
   
Modafinil (Provigil)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Modafinil Tablet 100mg
Modafinil Tablet 200mg

Restriction: Initiation by specialist

 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary